

## Starpharma receives \$7.2 million R&D Tax Incentive refund

**Melbourne, Australia; 23 October 2023: Starpharma (ASX: SPL, OTCQX: SPHRY)** today announces it has received a \$7.2 million research and development (R&D) tax incentive refund under the Australian Federal Government's R&D Tax Incentive scheme. The tax refund relates to eligible domestic and international R&D activities across Starpharma's portfolio for the 2022/2023 financial year.

**Dr Jackie Fairley, CEO at Starpharma,** commented:

*"The R&D Tax Incentive offered by the Australian Government plays a vital role in supporting local companies like Starpharma to innovate and expand."*

*"Starpharma has developed three clinical-stage DEP® assets, based on its novel technology platform, with high commercial and therapeutic potential. In this period, Starpharma has completed Phase 2 programs and, subsequently, released positive results from multiple clinical trials. In addition, the Company has progressed its DEP® radiotheranostic and DEP® antibody-drug conjugates pipeline, both of which are exciting, innovative areas of cancer therapy."*

*"Starpharma has also developed and commercialised a number of products that are available in multiple markets. These include VIRALEZE™, a broad-spectrum antiviral nasal spray for respiratory viruses registered in over 35 countries, and VivaGel® BV, a non-antibiotic gel for the treatment and prevention of bacterial vaginosis, which is approved in more than 50 countries."*

The Australian Federal Government's R&D Tax Incentive scheme provides a tax offset to entities that engage in eligible R&D activities, promoting innovation and investment in important clinical development programs and research collaborations with Australian institutions. Investing in medical and scientific R&D not only supports high-value, knowledge-based jobs but also makes a significant contribution to the Australian economy while helping companies tackle critical health challenges.

---

### About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is a world leader in dendrimer technology for medical applications. As an innovative Australian biopharmaceutical company, Starpharma is focused on developing and commercialising novel therapeutic products that address significant global healthcare needs. Starpharma boasts a strong portfolio of products, partnerships, and intellectual property.

Starpharma's innovative technology is based on proprietary polymers called dendrimers, which are precise, synthetically manufactured, nanoscale molecules. The unique properties of dendrimers – including their size, structure, high degree of branching, polyvalency, and water solubility – are advantageous in medical and pharmaceutical applications.

Starpharma uses its dendrimer technology to develop novel therapeutics and to improve the performance of existing pharmaceuticals. Starpharma's portfolio includes multiple clinical-stage oncology products, which utilise its Dendrimer Enhanced Product ("DEP®") drug delivery technology, and marketed products, including VIRALEZE™ and VivaGel® BV, which utilise SPL7013, a proprietary dendrimer with antimicrobial properties.

Starpharma's DEP® drug delivery platform is being used to enhance the effectiveness of existing and novel therapies and to reduce drug-related toxicities through controlled and specified drug delivery.

In addition to Starpharma's internal DEP® programs, Starpharma has multiple DEP® partnerships with international biopharmaceutical companies, including AstraZeneca (oncology), MSD (Antibody-Drug Conjugates), Chase Sun (anti-infectives), and other world-leading pharmaceutical companies. Due to the broad applicability and optionality of Starpharma's DEP® platform, partnered DEP® programs have the potential to generate significant future milestones and royalties.

Starpharma's topical antiviral nasal spray, VIRALEZE™, is now registered in more than 35 countries\*, including Europe, the UK, and Asia. Starpharma's novel non-antibiotic vaginal gel, VivaGel® BV, for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV, is registered in more than 50 countries, including in the UK, Europe, Southeast Asia, South Africa, Australia and New Zealand.

For more information about Starpharma, visit [www.starpharma.com](http://www.starpharma.com) or connect with Starpharma on [LinkedIn](#).

**WE Communications**

Hannah Howlett  
+61 450 648 064  
[WE-AUStarPharma@we-worldwide.com](mailto:WE-AUStarPharma@we-worldwide.com)

**Starpharma Holdings Limited**

Dr Jackie Fairley, Chief Executive Officer  
Justin Cahill, CFO and Company Secretary  
+61 3 8532 2704  
[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)  
4-6 Southampton Crescent  
Abbotsford Vic 3067

**Disclosure**

This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas.

**Forward-Looking Statements**

This document contains certain forward-looking statements relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", "outlook", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance, and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of any Starpharma product.